Adenovirus Viremia and Disease: Comparison of T Cell-Depleted and Conventional Hematopoietic Stem Cell Transplantation Recipients from a Single Institution

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 387-392

  Lee, Yeon Joo ^a   Chung, Dick ^a   Xiao, Kun ^a   Papadopoulos, Esperanza B ^a,b   Barker, Juliet N ^a,b   Small, Trudy N ^a,b   Giralt, Sergio A ^a,b   Zheng, Junting ^a   Jakubowski, Ann A ^a,b   Papanicolaou, Genovefa A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bone marrow transplantation; Infection; Mortality; Polymerase chain reaction; Risk factor; Virus

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS INFECTION; ADULT; ARTICLE; DISEASE ASSOCIATION; FECES ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; OBSERVATIONAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; QUANTITATIVE ANALYSIS; RECIPIENT; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; T CELL DEPLETION; VIREMIA; VIRUS LOAD;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIREMIA;

EID: 84873707308     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.10.014     Document Type: Article

References (41)

1. Flomenberg P., Babbitt J., Drobyski W.R., et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994, 169:775-781.
2. Symeonidis N., Jakubowski A., Pierre-Louis S., et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transplant Infect Dis 2007, 9:108-113.
3. Howard D.S., Phillips I.G., Reece D.E., et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999, 29:1494-1501.
4. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
5. Zaia J.A. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002, 35:999-1004.
6. Zaia J., Baden L., Boeckh M.J., et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009, 44:471-482.
7. Ohrmalm L., Lindblom A., Omar H., et al. Evaluation of a surveillance strategy for early detection of adenovirus by PCR of peripheral blood in hematopoietic SCT recipients: incidence and outcome. Bone Marrow Transplant 2011, 46:267-272.
8. Bil-Lula I., Ussowicz M., Rybka B., et al. PCR diagnostics and monitoring of adenoviral infections in hematopoietic stem cell transplantation recipients. Arch Virol 2010, 155:2007-2015.
9. Omar H., Yun Z., Lewensohn-Fuchs I., et al. Poor outcome of adenovirus infections in adult hematopoietic stem cell transplant patients with sustained adenovirus viremia. Transplant Infect Dis 2010, 12:465-469.
10. Ganzenmueller T., Buchholz S., Harste G., et al. High lethality of human adenovirus disease in adult allogeneic stem cell transplant recipients with high adenoviral blood load. J Clin Virol 2011, 52:55-59.
11. Walls T., Hawrami K., Ushiro-Lumb I., et al. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary?. Clin Infect Dis 2005, 40:1244-1249.
12. Lion T., Kosulin K., Landlinger C., et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia 2010, 24:706-714.
13. Schilham M.W., Claas E.C., van Zaane W., et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis 2002, 35:526-532.
14. Grimley M.S., Marsh R.A., Bleesing J.J., et al. Cmx001 as therapy for severe adenovirus infections in immunocompromised pediatric patients: single experience in 5 patients. Biol Blood Marrow Transplant 2012, 18:S315. S315.
15. Florescu D.F., Pergam S.A., Neely M.N., et al. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012, 18:731-738.
16. Jakubowski A.A., Small T.N., Kernan N.A., et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 2011, 17:1335-1342.
17. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
18. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
19. Heller G., Venkatraman E.S. Resampling procedures to compare two survival distributions in the presence of right-censored data. Biometrics 1996, 52:1204-1213.
20. La Rosa A.M., Champlin R.E., Mirza N., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001, 32:871-876.
21. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
22. Leen A.M., Christin A., Khalil M., et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008, 82:546-554.
23. Lion T., Baumgartinger R., Watzinger F., et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003, 102:1114-1120.
24. Anderson E.J., Guzman-Cottrill J.A., Kletzel M., et al. High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant 2008, 12:219-227.
25. Chakrabarti S., Mautner V., Osman H., et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002, 100:1619-1627.
26. Ottinger H.D., Beelen D.W., Scheulen B., et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996, 88:2775-2779.
27. Small T.N., Papadopoulos E.B., Boulad F., et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999, 93:467-480.
28. Fowler C.J., Dunlap J., Troyer D., et al. Life-threatening adenovirus infections in the setting of the immunocompromised allogeneic stem cell transplant patients. Adv Hematol 2010, 2010. Article ID: 601548.
29. Ljungman P., Ribaud P., Eyrich M., et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003, 31:481-486.
30. Robin M., Marque-Juillet S., Scieux C., et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007, 92:1254-1257.
31. Yusuf U., Hale G.A., Carr J., et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006, 81:1398-1404.
32. Bhadri V.A., Lee-Horn L., Shaw P.J. Safety and tolerability of cidofovir in high-risk pediatric patients. Transplant Infect Dis 2009, 11:373-379.
33. Erard V., Huang M.L., Ferrenberg J., et al. Quantitative real-time polymerase chain reaction for etection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis 2007, 45:958-965.
34. National Institutes of Health. Chimerix, a randomized, placebo-controlled multi-site phase 2 study evaluation the safety and efficacy of preemptive treatment with CMX001 for the prevention of adenovirus disease following hematopoietic stem cell transplantation in adults and children. Available from:. Accessed May 17, 2012. http://clinicaltrials.gov/show/NCT01241344.
35. Leen A.M., Christin A., Myers G.D., et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009, 114:4283-4292.
36. Hanley P.J., Cruz C.R., Savoldo B., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
37. Sili U., Leen A.M., Vera J.F., et al. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy 2012, 14:7-11.
38. Gerdemann U., Keirnan J.M., Katari U.L., et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012, 20:1622-1632.
39. Pagliara D., Savoldo B. Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients. Curr Opin Infect Dis 2012, 25:431-437.
40. Gerdemann U., Vera J.F., Rooney C.M., et al. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp 2011, 51:2736.
41. Karlsson H., Brewin J., Kinnon C., et al. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. J Immunother 2007, 30:544-556.